Promoter holding
64.27%
SP
Senores Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Senores Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distres…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Senores Pharmaceuticals — 360° Intelligence Report
Generated from MCA filings & public records85/100
Trust Score
Low Risk
Senores Pharmaceuticals is assessed as Low Risk with a Trust Score of 85/100. Senores Pharmaceuticals is an active public limited indian non-government company incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Senores Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
82/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 4 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 7 open (115.14 cr) · 4 satisfied (130.75 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 7 | 48.0 cr |
| Others | 3 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 82/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- 2 auditor resignation(s) filed - latest: Parikh & Majmudar on 2024-02-06.
- Delayed payments to MSME suppliers disclosed (10 disclosure(s)).
- 2 active GST registration(s).
05
Director Intelligence
Stability score: 75/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SANJAY SHAILESHBHAI MAJMUDAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHOKBHAI VIJAYSINH BAROT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SWAPNIL JATINBHAI SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Naresh Bansilal Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Hemanshu Nitinchandra Pandya | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Chetan Bipinchandra Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KALPIT RAJESH GANDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| UDAYAN DILEEP CHOKSI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JITENDRA BABULAL SANGHVI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARPIT DEEPAKKUMAR SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEVAL RAJNIKANT SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANJULA DEVI SHROFF | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Deval Rajnikant Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- No disqualified or deactivated DINs.
- 9 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
10 allotment(s) · 5 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Senores Pharmaceuticals Inc | Subsidiary Company | 74.00% |
| Ratnatris Pharmaceuticals Private Limited | Subsidiary Company | 74.00% |
| Havix Group Inc. D/b/a Aavis Pharmaceuticals | Subsidiary Company | 74.00% |
Key managerial personnel: SWAPNIL JATINBHAI SHAH (Managing Director) · Chetan Bipinchandra Shah (Whole-time director) · DEVAL RAJNIKANT SHAH (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 3 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 8 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
7 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 1.93 Lakh.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence85/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 7 open charge(s) of 115.14 cr already registered.
- Compliance record supports lending.
Investor view91/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events13 Nov 2025
Charge created
Hdfc Bank Limited - 23.00 Lakh
18 Sep 2025
Last AGM held
Annual general meeting
26 Jun 2025
Charge created
Hdfc Bank Limited - 44.60 Lakh
02 May 2025
Charge created
Hdfc Bank Limited - 35.10 Lakh
31 Mar 2025
Latest balance sheet
Filed with ROC
17 Mar 2025
Charge satisfied
Others
13 Feb 2025
Charge created
Others - 45.00 cr
12 Feb 2025
Charge satisfied
Hdfc Bank Limited
07 Dec 2024
Charge created
Hdfc Bank Limited - 11.29 Lakh
05 Oct 2024
Charge created
Others - 43.55 cr
24 May 2024
Director ceased
Hemanshu Nitinchandra Pandya
Director ceased
Chetan Bipinchandra Shah
Director ceased
UDAYAN DILEEP CHOKSI
20 May 2024
Director appointed
Deval Rajnikant Shah (Cfo)
01 May 2024
Director appointed
DEVAL RAJNIKANT SHAH (CFO)
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 3 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
13 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 10 security allotment(s) - amounts available in the full report.
34 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Synergy Air Products Private Limited | U40200PN2005PTC021168 | Pune - 412 208, Maharashtra, India |
| Bharat Carbonates Private Limited | U24321GJ1997PTC032820 | Surat, Gujarat, India |
| Advanced Enzyme | L24200MH1989PLC051018 | Thane, Maharashtra, India |
| Walparnutritions | L24230GJ2020PLC118662 | Gandhinagar, Gujarat, India |
| Medcell Pharma Private Limited | U24230HR2022PTC106564 | Gurugram, Haryana, India |
| Axxelent Pharma Science Private Limited | U24110TN2019PTC131943 | Chennai, Tamil Nadu, India |
| Sance Laboratories Private Limited | U24231KL2001PTC014957 | Kottayam, Kerala, India |
| Sotac | L24230GJ2015PLC085451 | Sanand, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Senores Pharmaceuticals before audits and certifications: compliance score 82/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Senores Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Senores Pharmaceuticals - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Senores Pharmaceuticals pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Senores Pharmaceuticals - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Senores Pharmaceuticals an active company?
Senores Pharmaceuticals has MCA status “Active” with a compliance score of 82/100 (Low Risk).
Is Senores Pharmaceuticals financially healthy?
Senores Pharmaceuticals has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Senores Pharmaceuticals?
Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Senores Pharmaceuticals?
Promoters hold a minority stake - exact percentages are in the full report. 13 active director(s) are on record.
Does Senores Pharmaceuticals have loans or charges against its assets?
7 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.
Is Senores Pharmaceuticals up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 82/100 (Low Risk).
Is it risky to lend to Senores Pharmaceuticals?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
